Becton, Dickinson and Company
One Becton Drive
Franklin Lakes
New Jersey
07417
United States
Tel: 201-847-6800
Fax: 201-847-6475
Website: http://www.bd.com/
866 articles about Becton, Dickinson and Company
-
BD Board Declares Dividend - Jan 25, 2022
1/25/2022
The Board of Directors of BD has declared a quarterly dividend of $0.87 per common share, payable on March 31, 2022 to holders of record on March 10, 2022.
-
BD Innovation Profiled in Cover Story of 'Science' Demonstrates Landmark Advancement in Flow Cytometry Technology
1/20/2022
BD announced that a study conducted in collaboration with the European Molecular Biology Laboratory and published as the cover story of the January 21st issue of the journal, Science, profiles a new BD innovation in flow cytometry that adds fluorescence imaging and image-based decisioning to sort individual cells at exceptionally high speed, based on the visual details of each cell and not solely on the type or quantity of biomarkers that are present.
-
BD Introduces Smart Connected Robotics to Automate Microbial Identification
1/7/2022
BD Kiestra™ IdentifA Receives 510(K) Clearance for Automated Sample Processing and MALDI Target Preparation.
-
BD Publishes 2021 Cybersecurity Annual Report
1/6/2022
BD (Becton, Dickinson and Company) today released its second annual cybersecurity report to update stakeholders on the state of health care cybersecurity.
-
BD Announces Change to Virtual 2022 Annual Meeting of Shareholders
1/6/2022
BD, a leading global medical technology company, announced that in the interest of the health and safety of its shareholders, directors, officers, employees and meeting attendees in light of the current and ongoing COVID-19 pandemic, the format of its 2022 Annual Meeting of Shareholders has been changed to a virtual-only meeting.
-
BD To Announce Financial Results For Its First Quarter Of Fiscal Year 2022
1/5/2022
BD announced that it will report financial results for its first quarter of fiscal year 2022 on Thursday, Feb. 3, 2022.
-
BD Announces New Distribution and Retail Partners for BD Veritor™ At-Home COVID-19 Test
12/22/2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical company, today announced the BD Veritor™ At-Home COVID-19 Test is now available for purchase through Everly Health.
-
BD Acquires Scanwell Health, Inc. to Expand and Scale Digital At-Home Testing
12/21/2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of privately held Scanwell Health Inc., a leader in smartphone-enabled at-home medical tests.
-
BD Announces Board of Directors for embecta, the Planned Spinoff of its Diabetes Care Business
12/21/2021
BD announced that Embecta Corp., the independent, publicly-traded company that will hold BD's Diabetes Care business upon the planned completion of the previously announced spinoff, will be governed by a nine-person board of directors.
-
BD Expands Fully Automated High-Throughput Molecular Diagnostic Platform for Core Labs
12/17/2021
BD COR™ MX for Infectious Disease Testing Receives CE Mark and is Final Instrument Introduced on BD COR™ System.
-
BD Acquires Tissuemed, Ltd. To Add Advanced Sealant To Its Portfolio Of Surgical Solutions
12/9/2021
Acquisition complements BD's core portfolio - adding an innovative, broadly applicable surgical sealant to a suite of BD biosurgery products already relied upon in the operating room.
-
BD Selects embecta as Name of New Company for Planned Spinoff of Diabetes Care Business; Announces Remainder of Leadership Team
12/6/2021
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that " embecta " [pronounced em-BECK-tah] will be the name of the independent, publicly-traded company that will hold BD's Diabetes Care business upon the completion of the previously announced spinoff.
-
BD Acquires Venclose, Inc. To Extend Treatment Innovations In Chronic Venous Disease
12/2/2021
BD (Becton, Dickinson and Company) announced today it has acquired Venclose, Inc., a provider of solutions for the treatment of chronic venous insufficiency (CVI) — a disease that is the result of malfunctioning valves and can lead to varicose veins.
-
BD Issues 2021 Global Inclusion, Diversity and Equity Report
12/1/2021
Progress Builds Strong Foundation for Bold 2030+ ESG Goals to Advance the World of Health for All.
-
BD Statement on Testing for the COVID-19 Omicron Variant of Concern
11/30/2021
BD (Becton, Dickinson and Company) today issued the following statement regarding testing for the COVID-19 Omicron variant of concern.
-
BD Names Dr. Joseph M. Smith as Chief Scientific Officer
11/29/2021
Digital Health Pioneer to Focus on External Innovation; Becomes Co-Chair of BD Scientific Advisory Board.
-
BD Names Francesca DeMartino as Senior Vice President of Investor Relations
11/24/2021
BD (Becton, Dickinson and Company) today announced Francesca DeMartino has been named senior vice president of investor relations for the company, effective Nov. 29.
-
BD to Highlight Progress Against BD 2025 Strategy and Plans for Long-Term Growth
11/12/2021
BD, a leading global medical technology company, will begin its Investor Day at 8 a.m. ET to share how it plans to leverage the breadth and depth of its core portfolio to fuel a new wave of growth through transformative solutions that can help reinvent health care.
-
QIAGEN and BD Settle Patent Infringement Lawsuit
11/5/2021
QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) and BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that they have reached a settlement in the patent infringement lawsuit related to QIAGEN’s NeuMoDx™ 96 and NeuMoDx™ 288 clinical PCR systems that QIAGEN acquired from NeuMoDx Inc. in 2020.
-
BD Board Increases Dividend for 50th Consecutive Year, Authorizes 10 Million Additional Share Repurchases
11/4/2021
The Board of Directors of BD has declared a quarterly dividend of $0.87 per common share, an increase of 4.8% from the previous quarter.